Merck’s Geographic Footprint Grows A Size (Or Two) With Schering Buy
This article was originally published in The Pink Sheet Daily
Merck’s international sales will more than double to $25 billion with the acquisition of Schering-Plough.
You may also be interested in...
Patent expiries for five products drag down revenue, but biotech deals and pipeline building remain Merck’s strategy, CEO Frazier says.
$41.1 bil. acquisition will create a cardiovascular powerhouse, buffer Merck against patent expirations of Singulair, Cozaar/Hyzaar and generate $3.5 bil in savings.
After much talk of a major acquisition, Schering buys the Organon pharmaceutical and animal health business of Akzo Nobel.